THERAPIES IN ENDOMETRIAL CANCER WITH DNA MISMATCH REPAIR DEFICIENT OR MICROSATELLITE INSTABILITY: A SYSTEMATIC REVIEW

C. MORENO RAMOS[1], M.D. GIL-SIERRA[2], M.D.P. BRICEÑO-CASADO[2], M. REYES MALIA[3], E. CAMPOS DÁVILA[4].
[1]SERVICIO ANDALUZ DE SALUD, FARMACIA HOSPITALARIA, CÁDIZ, SPAIN. [2]HOSPITAL UNIVERSITARIO JEREZ DE LA FRONTERA, FARMACIA HOSPITALARIA, JEREZ DE LA FRONTERA, SPAIN. [3]HOSPITAL INFANTA ELENA, FARMACIA HOSPITALARIA, HUELVA, SPAIN. [4]HOSPITAL DE LA LÍNEA DE LA CONCEPCIÓN, FARMACIA HOSPITALARIA, LA LÍNEA, SPAIN.

4CPS-184
L01- ANTINEOPLASTIC AGENTS

Background and importance

- Standard therapy for advanced endometrial cancer (EC) pre-treated with platinum-based chemotherapy (PCT) showed limited efficacy.
- DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) neoplasms are associated with increased PD-1 and PD-L1 expression. Thus, immunotherapy could play an important role in EC with dMMR/MSI-H.

Aim and objectives

To conduct a systematic review of scientific evidence on treatments for EC with dMMR/MSI-H in patients who previously received PCT

Material and methods

PRISMA methodology

A literature search in PubMed® database was performed until August 2023.

- Inclusion criteria: clinical trials (CTs) involving patients with dMMR, or MSI-H diagnosed with advanced and/or metastatic EC who had previously received PCT.
- Efficacy endpoints: overall survival (OS), progression-free survival (PFS) and objective response rate (ORR).
- Data collected: publication date, study design, stage, median patient follow-up, sample size, therapies, comparator arm and efficacy data.

Results

30 search results → 13 CTs met the inclusion criteria.

- 11 studies had no comparator arm.
- Median follow-up: 6 - 42.6 months.
- Sample size: 11 - 130 patients.
- Therapies: pembrolizumab, pembrolizumab + lenvatinib, durvalumab, durvalumab + tremelimumab, dostarlimab, nivolumab and avelumab.

Pembrolizumab achieved the highest numerical efficacy.

Dostarlimab and durvalumab presented the next best numerical efficacy.

Therapy	OS	PFS	ORR
Pembrolizumab	40.0 months (95%CI 25.3-NR)	23.5 months (95%CI 10.7-NR)	58% (95%CI 37-78)
Dostarlimab	NR	12.2 months (95%CI not available)	43.5% (95%CI 34.5-53.4)
Durvalumab	NR	8.3 months (95%CI 2.4-NR)	47% (95%CI 32-63)]

Conclusion and relevance

The greatest numerical efficacy data were achieved by pembrolizumab, followed by dostarlimab and durvalumab. CTs with adequate comparisons are needed for reliable data interpretation